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Abstract: Surgical site infections (SSIs) represent the most common nosocomial infections, and surgical
sutures are optimal surfaces for bacterial adhesion and biofilm formation. Staphylococcus spp.,
Enterococcus spp., and Escherichia coli are the most commonly isolated microorganisms. The aim
of this research was to evaluate the antibiofilm activity of a medical device (MD) containing
TIAB, which is a silver-nanotech patented product. The antibacterial effect was evaluated against
Staphylococcus aureus ATCC 29213, Enterococcus faecalis ATCC 29212, and E. coli ATCC 25922 by assessing
the minimum inhibitory concentration (MIC) by the Alamar Blue® (AB) assay. The antibiofilm
effect was determined by evaluation of the minimum biofilm inhibitory concentration (MBIC) and
colony-forming unit (CFU) count. Subsequently, the MD was applied on sutures exposed to the
bacterial species. The antimicrobial and antibiofilm effects were evaluated by the agar diffusion
test method, confocal laser scanning microscopy (CLSM), and scanning electron microscopy (SEM).
The MIC was determined for S. aureus and E. faecalis at 2 mg/mL, while the MBIC was 1.5 mg/mL
for S. aureus and 1 mg/mL for E. faecalis. The formation of an inhibition zone around three different
treated sutures confirmed the antimicrobial activity, while the SEM and CLSM analysis performed on
the MD-treated sutures underlined the presence of a few adhesive cells, which were for the most part
dead. The MD showed antimicrobial and antibiofilm activities versus S. aureus and E. faecalis, but a
lower efficacy against E. coli. Surgical sutures coated with the MD have the potential to reduce SSIs as
well as the risk of biofilm formation post-surgery.
Keywords: Staphylococcus aureus; Enterococcus faecalis; antimicrobial activity; antibiofilm activity;
surgical site infection; TIAB
Molecules 2019, 24, 2280; doi:10.3390/molecules24122280 www.mdpi.com/journal/molecules
Molecules 2019, 24, 2280 2 of 15
1. Introduction
Surgical site infections (SSIs) are classified as ”infections occurring within 30 days after a surgical
operation (or within one year if an implant is left in place after the procedure) and affecting either
the incision or deep tissue at the operation site” [1,2]. SSIs represent the most common nosocomial
infections and account for 14–16% of all healthcare-associated infections among hospitalized patients
and 38% among surgical patients [2,3]. SSIs are the cause of morbidity and in some cases mortality [4],
and increase healthcare costs, since they imply a prolonged hospitalization, additional diagnostic tests,
massive antibiotics use, and sometimes invasive surgery. Surgical sutures represent a suitable substrate
for microbial adhesion and, therefore, for biofilm formation. A significant rate of hospital-acquired
infections is associated with biofilms developed by pathogens and/or opportunistic pathogens. A biofilm
is a microbial community protected by a self-produced complex matrix of extracellular polymeric
substances (EPS) adherent to each other and/or to a surface that protects the microorganisms from the
attack by the antimicrobials and the host immune system [5,6].
As reported by Koo et al., the biofilm was initially described as the “arcane behavior of
bacterial populations”, but it is currently described as a “principle virulence factor in many localized
chronic infections”. The infections associated with biofilm usually develop after a long period of
hospitalization, and the microbial community of the biofilm may develop tolerance to the antibiotics
using different strategies such as the entry into a dormancy or viable but non-culturable (VBNC)
status or the development of molecular pathways that guarantee their persistence and survival [7].
Therefore, the biofilm EPS matrix plays an important role in conferring antimicrobial tolerance to
biofilms [6,7]. The bacteria more commonly isolated by SSIs are Staphylococcus spp., Enterococcus spp.,
and E. coli; however, the microorganisms that are isolated could depend on the type of surgery [2,8].
Many approaches have been developed for the in vitro treatment of the biofilms.
Metals and metal oxide nanomaterials have been widely studied for their applications in the
clinical field because of their innovative size and properties. Titanium dioxide (TiO2) nanotubes have
been used such as for biosensors, drug delivery systems, and cancer therapy [9]. The antimicrobial
activity of metals such as silver (Ag), copper, gold, titanium, and zinc, which are characterized
by different properties and spectra of action, have been known for centuries [9,10]. Aydin et al.
demonstrated that Ag-doped TiO2 nanotubes could be used as an effective material that is free of
antimicrobial resistance [9]. Other researchers showed that TiO2 microspheres combined with Ag
particles possess antimicrobial properties, particularly versus S. aureus and E. coli, suggesting an
application in dentistry, orthopedics, and other field of medicine [11,12]. However, TiO2 as well as
ZnO nanomaterials are the most studied for their activity not only toward bacterial infections, but also
toward viral, fungal, and protozoal infections [13]. The antimicrobial activity is performed through the
induction of the production of reactive oxygen species (ROS), which damage the cellular membrane
and cause the peroxidation of proteins and lipids. Recently, Peiris et al. showed that the antimicrobial
activity of TiO2 nanoparticles biosynthesized by using Backer’s yeast was greater versus Gram-positive
bacteria and Candida albicans than versus Gram-negative ones [14]. Noble metals such as Ag are often
used to modify oxide-based semiconductors for improving the antimicrobial activity [15].
Furthermore, silver nanoparticles are widely studied for their application in wound healing
because of their physicochemical and biological properties. Silver nanoparticles are non-cytotoxic
and safe, and can be used for the preventive control of the growth of microorganisms in the site
of infection [16,17]. Nanoparticles are considered an alternative strategy to the use of the common
antibiotics. It was demonstrated that nanoparticles work discharging toxic metal ions or by inducing
the production of reactive oxygen species (ROS) [17]. The negatively-charged groups on the bacterial
surfaces attracted positively charged nanoparticles, inducing the formation of channels on the bacterial
cell wall [18,19]. Nanoparticles are capable of penetrating the bacterial cell wall and affecting the
metabolic pathways and proton eﬄux pumps, inducing a modification of the pH and membrane surface
charges [20]. The efficacy of nanoparticles used alone or functionalized with antibiotics or natural
compounds have been studied for application in wound healing [19]. In particular, silver nanoparticles
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have been studied for wound dressing in pressure ulcers or coat polyester–nylon wound dressing for
reducing the risk of Pseudomonas aeruginosa and S. aureus infections [21,22].
The main aim of the present investigation was to establish the antibiofilm activity of a medical
device (MD) containing TIAB, which consists of microcrystalline titanium dioxide (TiO2) nanoparticles
(100 to 500 nm) covalently linked with monovalent silver ions (Ag+), commercially available under the
trademark Peonil®. The antibiofilm activity was evaluated on microorganisms, biofilm-producers,
associated with SSIs in the male urogenital tract. The medical device used is characterized by
different components with complementary pharmacological activities such as TIAB, which is the silver
preparation, Aloe vera extract, and hyaluronic acid. The other two major components were shown to
display anti-inflammatory and healing effects on damaged epithelium, forming a protective barrier
against external noxae. This complex mixture helps treating/slowing infections caused by bacteria,
fungi, and viruses, including the genital herpes virus (HSV-2). It is also involved in tissue regeneration
and wound healing after surgery. To the best of our knowledge, this medical device has been never
tested for its antimicrobial/antibiofilm activity or its efficacy after treatment on three commercially
available braided surgical sutures exposed to different microorganisms despite its use in the clinical
treatment/prevention of SSIs. The sutures were selected on the basis of their common use after surgery
and their differences in terms of material, absorption, and diameter.
2. Results and Discussion
The antimicrobial and antibiofilm effects of the MD were evaluated against three reference
strains: S. aureus ATCC 29213, E. faecalis 29212, and E. coli 25922 (Table 1). The minimum inhibitory
concentration (MICs) were determined by using the broth micro-dilution method, according to the
Clinical and Laboratory Standards Institute (CLSI) guidelines. The results obtained were confirmed by
the AB reduction assay, which represents a cell health indicator. The kit contains resazurin, which is a
non-toxic, cell-permeable, blue, non-fluorescent molecule that is reduced to resorufin, which is red in
color, and is a fluorescent compound when the cells are alive (Figure 1A,B). The MD displayed an MIC
corresponding to 2 mg/mL versus S. aureus and E. faecalis (Table 1 and Figure 1A,B); on the contrary,
no antimicrobial effect was detected against E. coli, which showed MIC >8 mg/mL.
Table 1. Evaluation of the minimum inhibitory concentration (MIC), minimum bactericidal
concentration (MBC), and minimum biofilm inhibitory concentration (MBIC) of the medical device
(MD) against S. aureus, E. coli, and E. faecalis.
Bacterial Strains MIC (mg/mL) MBC (mg/mL) MBIC (mg/mL)
S. aureus ATCC 29213 2 4 1.5
E. coli ATCC 25922 >8 >8 n.t.
E. faecalis ATCC 29212 2 4 1
n.t.: not tested.
With regard to MBC, the MD was shown to be effective at 4 mg/mL versus S. aureus and E. faecalis
(Table 1); this was different from E. coli, which showed MBC > 8 mg/mL (Table 1; Figure 1C). The MD
showed antimicrobial and antibiofilm activities versus S. aureus and E. faecalis, but a lower efficacy
against E. coli. The antimicrobial activity is definitely due to the silver-based component (TIAB),
because the antibacterial activity exerted by silver ions as well as by TiO2 nanoparticles has long been
known [13,23]. TIAB can be used as an effective topic therapeutic agent in the treatment of chronic
periodontitis along with supportive periodontal therapy and after ocular surgery. Lauritano et al.
demonstrated the antimicrobial effect of TIAB against red complex organisms; in particular, a significant
reduction of Treponema denticola and Porphyromonas gingivalis was observed [24]. The effect of TIAB has
been the topic of medical studies, especially in the dermatological field [25]. Silver ions are capable of
inducing bacterial death by different pathways: (i) bacterial proteins inactivation, (ii) the inhibition of
DNA replication, (iii) the modulation of gene expression, (iv) blockade of the electron transport chain
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with the consequent reduction of ATP, and ultimately, interference with signaling pathways, which are
essential for bacterial survival [23]. Since the MD has shown efficacy exclusively toward S. aureus
and E. faecalis, the minimal biofilm inhibitory concentration (MBIC) was evaluated versus these two
bacterial species. As regards growth inhibition, it is not unexpected to register limited activity against
Gram-negative species due to both the presence of an outer membrane that is difficult to penetrate and
overexpressed eﬄux pumps.
The MD also showed the capability of inhibiting the development of a mature biofilm by S.
aureus and E. faecalis. In particular, the MBIC was determined by using AB assay, CFU counting, and
live/dead staining, followed by fluorescent microscopy analysis. The MD displayed MBIC at 1.5 mg/mL
toward S. aureus and 1 mg/mL toward E. faecalis (Table 1 and Figure 2A,B). The microscopy analysis
showed the development of a mature biofilm for both strains after 24 h of incubation (Figure 2C, a
and c). On the contrary, the samples treated with the MD showed no biofilm formation with few
live cells adhered onto the plate surface (Figure 2C). The inhibition of the biofilm development in the
treated samples was confirmed by a statistical significant reduction of CFU compared to the controls
(Figure 2D, b and d). The capability of MD to inhibit biofilm formation is probably due by interfering
with quorum sensing. It has been demonstrated that silver ions are capable of penetrating through
the biofilm matrix, where they are less susceptible to modifications compared to common drugs [26].
The Ag+–TiO2 nanoparticles are able to interfere with the microbial quorum sensing affecting the
biofilm development [23]. The surgical sutures represent an optimal substrate for the bacterial cells
adhesion, and thus biofilm development. Therefore, the capability of MD to inhibit S. aureus and E.
faecalis biofilm formation was evaluated on three sutures having different characteristics. The sutures
were treated and non-treated with the MD as indicated in the Material and Methods section.
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determined by Alamar Blue® (AB) assay, which is based on the chemical reduction of resazurin (a 
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environment. (A) Representative image of colorimetric MIC determination using AB assay. The black 
Figure 1. Evaluation of m nimum inh bitory concentration (MIC) and minimum bactericidal
concentration (MBC) of the medical device (MD) versus S. aureus, E. coli, and E. faecalis. The MIC was
determined by Alamar Blue® (AB) assay, which is based on the chemical reduction of resazurin (a
non-toxic, cell-permeable, non-fluorescent, blue compound) in resorufin, which is a highly fluorescent
red/purple compound. Such reduction is performed by viable cells; therefore, continued cell growth
maintains a reduced environment, while the inhibition of growth or cell death induces an oxidized
environment. (A) Representative image of colorimetric MIC determination using AB assay. The black
circle indicates the MIC at 2 mg/mL which is the same for both S. aureus and E. faecalis. (B) The
plot shows the percentage reduction of AB recorded for the three bacterial species at different MD
concentrations compared to the corresponding untreated samples (0.00) performed as described in the
Materials and Methods section. The percentage of AB reduction was evaluated by using absorbance at
570 nm and 600 nm. (C) The MBC was determined by CFU counts and corresponds to 4 mg/mL for S.
aureus and E. faecalis. Data are the mean of three replicates of three independent experiments; * p < 0.05
vs. the controls (0.00). C: controls or untreated samples.
Figure 1. Cont.
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non-toxic, cell-permeable, non-fluorescent, blue compound) in resorufin, which is a highly fluorescent
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circle indicates the MIC at 2 mg/mL which is the same for both S. aureus and E. faecalis. (B) The
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Figure 1. Evaluation of minimum inhibitory concentration (MIC) and minimum bactericidal
concentration (MBC) of the medical device (MD) versus S. aureus, E. coli, and E. faecalis. The MIC was
determined by Alamar Blue® (AB) assay, which is based on the chemical reduction of resazurin (a
non-toxic, cell-permeable, non-fluorescent, blue compound) in resorufin, which is a highly fluorescent
red/purple compound. Such reduction is performed by viable cells; therefore, continued cell growth
maintains a reduced environment, while the inhibition of growth or cell death induces an oxidized
environment. (A) Representative image of colorimetric MIC determination using AB assay. The black
circle indicates the MIC at 2 mg/mL which is the same for both S. aureus and E. faecalis. (B) The
plot shows the percentage reduction of AB recorded for the three bacterial species at different MD
concentrations compared to the corresponding untreated samples (0.00) performed as described in the
Materials and Methods section. The percentage of AB reduction was evaluated by using absorbance at
570 nm and 600 nm. (C) The MBC was determined by CFU counts and corresponds to 4 mg/mL for S.
aureus and E. faecalis. Data are the mean of three replicates of three independent experiments; * p < 0.05
vs. the controls (0.00). C: controls or untreated samples.
The efficacy of the MD was demonstrated by the agar diffusion test method, scanning electron
microscopy (SEM) and confocal laser scanning microscopy (CLSM). The formation of an inhibition
zone around the treated multifilament sutures confirmed the MD antimicrobial activity; in fact, TIAB
is able to diffuse in the agar inhibiting the S. aureus growth (Figure 3A,C and E), while the SEM and
CLSM analysis underlined the presence of few adhered cells on the MD-treated sutures with respect
to the controls, which showed a well-structured biofilm characterized by numerous cell aggregates
(Figures 4 and 5). The same results were obtained against E. faecalis (Figure 6).Molecules 2019, 24, 0 6 of 16Molecul s 2018, 23, x FOR PEER REVIEW  7 of 17 
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Figure 2. Evaluation of minimum biofilm inhibitory concentration (MBIC) of the medical device (MD)
versus S. aureus and E. faecalis biofilm determined by AB assay, live/dead staining, and fluorescent
microscopy analysis and colony-forming unit (CFU) counts. (A) Representative image of colorimetric
MIC determination using AB assay. The black circle indicates the MBIC at 1.5 mg/mL, which is the
same for both S. aureus and E. faecalis. (B) The plot shows the percentage reduction of AB recorded for S.
aureus and E. faecalis at different MD concentrations compared to the corresponding untreated samples
(0.00), as previously described. The percentage of AB reduction was evaluated by using absorbance
at 570 nm and 600 nm. (C) Representative images of live/dead staining of S. aureus and E. faecalis
biofilm developed with and without the addition of MD at the inoculum. S. aureus biofilm after 24 h of
incubation: (a) S. aureus treated with 1.5 mg/mL of MD at the inoculum, (b) E. faecalis biofilm after 24 h
of incubation, (c) E. faecalis treated with 1 mg/mL of MD, (d) the green fluorescence indicates live cells;
the samples treated with the MD did not develop a biofilm, as shown in images (b and d). bar: 5 µm.
(D) Evaluation of the CFU number in the MD-treated and untreated sample. A significant reduction
was detected at 1.50 mg/mL in both the microorganisms. Data are the mean of three replicates of three
independent experiments; * p < 0.05 vs. the controls (0.00). C: controls or untreated samples.
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Figure 2. Evaluation of minimum biofilm inhibitory concentration (MBIC) of the medical device (MD)
versus S. aureus and E. faecalis biofilm determined by AB assay, live/dead staining, and fluorescent
microscopy analysis and colony-forming unit (CFU) counts. (A) Representative image of colorimetric
MIC determination using AB assay. The black circle indicates the MBIC at 1.5 mg/mL, which is the
same for both S. aureus and E. faecalis. (B) The plot shows the percentage reduction of AB recorded
for S. aureus and E. faecalis at different MD concentrations compared to the corresponding untreated
samples (0.00), as previously described. The percentage of AB reduction was evaluated by using
absorbance at 570 nm and 600 nm. (C) Representative images of live/dead staining of S. aureus and
E. faecalis biofilm developed with and without the addition of MD at the inoculum. S. aureus biofilm
after 24 h of incubation: (a) S. aureus treated with 1.5 mg/mL of MD at the inoculum, (b) E. faecalis
biofilm after 24 h of incubation, (c) E. faecalis treated with 1 mg/mL of MD, (d) the green fluorescence
indicates live cells; the samples treated with the MD did not develop a biofilm, as shown in images
(b and d). bar: 5 µm. (D) Evaluation of the CFU number in the MD-treated and untreated sample.
A significant reduction was detected at 1.50 mg/mL in both the microorganisms. Data are the mean
of three replicates of three independent experiments; * p < 0.05 vs. the controls (0.00). C: controls or
untreated samples.
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Figure 3. Representative images of the inhibition zones on ueller-Hinton agar (MHA) plates of the
three different surgical sutures treated (A, C, E) and untreated (B, D, F) with the medical device (MD).
The efficacy of the MD versus S. aureus is demonstrated by the presence of an inhibition zone around
the treated sutures. Similar results have been obtained versus E. faecalis.
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Figure 4. Representative SEM images of sutures untreated and treated with the medical device (MD).
Panels A, B, and C represent different magnifications of untreated sutures with S. aureus cells adhered
on the surface of the threads. S. aureus aggregates forming a well-developed biofilm were visible on
panels B and C. On the contrary, few scattered cells were attached on the suture surface of MD-treated
samples (D, E, F).
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The image shows the S. aureus capability of forming an abundant biofilm on sutures without medical
device (MD) treatment.
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Figure 6. Representative SEM images of sutures untreated and treated with the medical device (MD).
Panels A, B, and C represent different magnifications of untreated sutures with E. faecalis cells adhered
on the surface of the threads. E. faecalis aggregates forming a biofilm were visible on panels B and C.
On the contrary, few cells were attached on the suture surface of MD-treated samples (D, E, F).
The data obtained demonstrated that bacteria adhere to these braided multifilament sutures,
although they prefer suture threads of silk composed of an organic protein called fibroin with respect
to synthetic ones (data not shown). The Alamar Blue reduction as well as the CFU counting and
live/dead assay displayed the efficacy of the MD in protecting the suture threads from microbial
colonization and biofilm formation (for S. aureus and E. faecalis). The SEM and CLSM analysis confirmed
the presence of a few bacterial cells, most of which were dead (indicated by the red fluorescence),
and adhered on MD-coated sutures compared to the non-treated controls, which showed the presence
of a well-structured biofilm characterized by live cells (green fluorescence) (Figure 7). However,
the data obtained can be underestimated, since the treated suture threads have been immersed in
Molecules 2019, 24, 2280 9 of 15
liquid medium; we cannot exclude a reduction in the MD effect due to dissolution of the cream in the
culture medium. In the same way, we cannot exclude the possible adhesion of bacterial cells in the
stitches of the suture thread not covered by cream. The interesting aspect is that TIAB explicates its
antibacterial and antibiofilm activity even when complexed with other components in the form of
cream, providing that this combination does not inhibit its efficacy. In addition, no differences in the
biofilm formation were registered on the three different braided multifilament sutures, thus confirming
the broad MD versatility after surgery, as demonstrated for triclosan-coated sutures [27].Molecules 2018, 23, x FOR PEER REVIEW  11 of 17 
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Figure 7. Representative images obtained by confocal laser scanning microscopy (CLSM) of S. aureus
and E. faecalis grown on sutures untreated and MD-treated, stained with BacLight kit (bar: 10 µm).
Green fluorescence indicates live cells, and red fluorescence indicate dead cells. In the untreated
samples, aggregates of live cells organized in a biofilm were visible. On the contrary, in the MD-treated
sutures, an increased number of dead cells was present.
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SSIs are responsible for complications after surgical operations despite antibiotic
prophylaxis [28,29]. SSIs represent 2–5%, but can reach 25%, as in the case of colorectal surgery [30].
Therefore, the use of antimicrobial-coated sutures such as the ones coated with triclosan [29,31]
might represent a possible approach. Several studies demonstrated the in vitro antimicrobial effect
of triclosan [32,33]. However, some studies demonstrated the development of bacterial resistance
versus triclosan, hypothesizing the possible selection of resistant bacterial strains [34,35]. In addition,
Obermeier et al. demonstrated the antimicrobial efficacy of chlorhexidine and octenidine applied on
surgical sutures, particularly versus S. aureus [36]. The antimicrobial and antibiofilm activities
of a commercially available MD (Peonil®), in the form of cream, when applied to the suture
threads, represent a valid strategy to reduce the risk of infection, particularly by biofilm-producer
microorganisms. Furthermore, the application of a cream formulation on surgical sutures could
avoid the use of coated sutures, which are more expensive and can induce side effects to the patients.
The therapy could be monitored and tailored according to the patient allowing the easy removal of the
cream in case of topical toxicity or allergy. We focalized the attention on bacterial species associated
with infections of male urogenital tract, since the present work represents the basis for the start of a
clinical trial to be implemented in male patients undergoing surgical operations in the urogenital tract.
However, the efficacy of the MD should be demonstrated also against microorganisms associated with
infections in other surgical sites.
3. Materials and Methods
3.1. Bacterial Strains and Culture Conditions
The antimicrobial activity of the medical device containing TIAB was evaluated on three reference
strains: S. aureus ATCC 29213, E. faecalis ATCC 29213, and E. coli ATCC 25922. The strains were cultured
on Mueller-Hinton agar (MHA, Oxoid Ltd., Hampshire, UK), Mannitol salt agar (MSA, Oxoid Ltd.,
Hampshire, UK), and MacConkey agar (MCKA, Oxoid Ltd., Hampshire, UK), respectively.
The reference strains were conserved at −80 ◦C before being melted at room temperature and
plated on tryptic soy agar (TSA; Oxoid Ltd., Hampshire, UK). Then, bacteria were grown in tryptic soy
broth (TSB; Oxoid Ltd., Hampshire, UK) for 16 h at 37 ◦C under shaking conditions at 125 rpm (Innova
4300, New Brunswick Scientific, Edison, NJ, USA).
3.2. Determination of Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal
Concentration (MBC)
The MIC and MBC were determined in Mueller-Hinton broth (MHB, Oxoid Ltd., Hampshire, UK)
by using the broth microdilution method in 96-well polystyrene microtiter plates (Eppendorf, Hamburg,
Germany) according to the Clinical and Laboratory Standards Institute (CLSI) [37]. The overnight
broth cultures were resuspended in Mueller-Hinton broth to an optical density (OD550) of 0.8 at 550 nm
corresponding to 1.0 × 108 colony-forming units (CFU)/mL. The broth cultures were diluted 1:100
in MHB and then 1:10 to reach a final concentration of 1.0 × 105 CFU/mL according to the CLSI
guidelines. The MD Peonil® (generously provided by Idi Pharma Srl, Catania, Italy) was diluted in
MHB to obtain the range of concentrations of 0.25 to 8 mg/mL. Controls included: (i) broth cultures
in MHB without the addition of MD; (ii) MHB with MD at different concentrations, and (iii) just
MHB. The plates were put into an incubator at 37 ◦C for 24 h. Three independent experiments were
carried out in triplicate. The MIC is defined as the lowest concentration of MD that fully inhibits the
growth of the microorganism in the microdilution wells as detected by an unaided eye. The MBC
is defined by registering the lowest concentration of MD that reduces the viability of the starting
bacterial inoculum by ≥99.9% (CLSI guidelines). The results obtained were confirmed by using the
Alamar Blue® (AB) (Thermo Fisher Scientific, Waltham, MA, USA) planktonic susceptibility assay,
as previously reported [38,39].
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3.3. Determination of Minimal Biofilm Inhibitory Concentration (MBIC)
The antibiofilm activity of MD was measured by the MBIC assay in 96-well polystyrene microtiter
plates. The wells were filled with MHB containing the broth cultures (105 CFU/mL) and MD
(0.5–1.5 mg/mL), and were incubated at 37 ◦C for 24 h. After the incubation, the supernatants were
removed and the biofilms were rinsed in phosphate-buffered saline (PBS), and AB was diluted in
sterile 0.01 M phosphate-buffered saline (PBS NaCl 0.138 M, KCl 0.0027 M; pH 7.4; Sigma-Aldrich,
Milan, Italy) at 10% and added to the biofilms following the manufacturer’s instructions. The plates
were incubated for 1 to 4 h at 37 ◦C; then, the percent reduction of AB was determined. Therefore, the
colony-forming unit counting method was carried out to evaluate bacterial cell viability in the biofilm.
Then, 100 µL of samples, taken from the MBIC wells, were used for CFU counts. Serial dilutions of the
stock were performed in phosphate-buffered saline (PBS) (pH 7.2) and plated on MHA. The plates
were incubated at 37 ◦C for 18–24 h. The same evaluation was performed in the case of the AB assay
because of its non-toxic nature.
3.4. Coating of the Sutures with the MD
In this study, three kinds of sterile surgical sutures were used to produce an antimicrobial suture
by coating: one non-absorbable multifilament Ethicon®Perma-hand silk suture composed of an
organic protein (fibroin) with 0.35 mm of diameter, and two internal absorbable multifilament sutures:
a Safil® Quick synthetic braided and coated suture made of 100% polyglycolic acid (PGA) with
0.2 mm of diameter, and Ethicon®-coated vicrylrapide synthetic suture composed of a copolymer
of 90% glycolide and 10% L-lactide with 0.15 mm of diameter. Following a previously reported
experimental procedure [29,36,40], the sutures were cut under sterile conditions to obtain filaments
that were 1.5 cm in length. Then, the sutures were dipped into the MD, followed by a drying period
of 2 h at 37 ◦C. The weight of each coating on the multifilament sutures was measured by means of
an analytical balance (XP205 Analytical Balance, Mettler Toledo, Columbus, OH, USA), before and
after dipping/drying, and the resulting drug concentration was expressed per unit of length after this
procedure. The amount of MD on each suture ranged from 2 to 7 mg/cm and thus was comparable or
higher after dilution into the broth cultures to the MBIC values registered for S. aureus and E. faecalis
(Table 1).
3.5. Antimicrobial and Antibiofilm Activity of the MD-Treated Sutures
The antimicrobial activity of sutures coated with MD was determined in MHA through the agar
diffusion test. According to CLSI criteria, suspensions of 1.0 × 105 CFU/mL of S. aureus and E. faecalis
were prepared as mentioned above. Then, 200 µL of the suspension were plated uniformly on MHA
plates and MD-treated, and untreated sutures were placed onto the surface. Then, the plates were
incubated at 37 ◦C for 24 h.
The antibiofilm activity of sutures coated with MD was tested through the bacterial adhesion assay.
Broth cultures of S. aureus and E. faecalis at the concentration of 1.0 × 105 CFU/mL were prepared as
mentioned above. The MD-treated and untreated sutures were inoculated with 2 mL of broth cultures
dispensed in six-well polystyrene microtiter plates (Eppendorf, Hamburg, Germany). Then, the plates
were incubated at 37 ◦C for 24 h in static conditions.
3.6. Scanning Electron Microscopy (SEM)
Scanning electron microscopy (SEM) was employed to analyze bacterial adhesion and
biofilm formation on MD-coated and untreated sutures. The sutures were rinsed with 0.1 M of
phosphate-buffered solution (PBS) at pH 7.1 and fixed overnight with a 4% PBS–paraformaldehyde
solution at 4 ◦C. Samples were further washed with PBS buffer and dehydrated using an ascending
alcohol series before mounting onto aluminum stubs and gold sputtering in an Emitech K 550
(Emitech Ltd., Ashford, Kent, UK).
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The samples were imaged by means of SEM with LaB6 electron beam (Zeiss EVO 50 XVP, Carl Zeiss
SMY Ltd., Cambridge, UK), coupled to tetra solid-state BSE detector. SEM operating conditions
comprehended 10 kV of accelerating voltage, a 10-mm working distance and a 1.2-nA probe current.
The observations were performed under variable pressure at 0.75 torr using both the BSE and SE1
detectors. The images were captured with a line average technique using 20 scans.
3.7. Confocal Laser Scanning Microscopy (CLSM) Analysis for Visualization of Adherent Bacteria
Live/dead staining and confocal laser scanning microscopy (CLSM) investigated bacterial viability
and biofilm formation on MD-treated and untreated sutures. The surgical suture samples were washed
in PBS to selectively remove the non-adhered bacteria, and stained with BacLight kit (Thermo Fisher
Scientific, Waltham, MA, USA) for 15 min at room temperature [41]. Then, sutures were washed in
PBS and visualized using a Zeiss LSM510 META confocal system (Carl Zeiss, Jena, Germany) coupled
to an inverted Zeiss Axiovert 200 microscope equipped with a Plan Neofluar oil-immersion objective
(100×/1.45 NA). The green and red emission (SYTO 9 and propidium iodide, respectively) were excited
using the 488 nm (4% of potency) of an argon laser and a helium/neon 543 nm source (2.5% of potency).
To separate the fluorescence emissions, HTF 488/543 and NTF 545 as primary and secondary dichroic
mirrors were used. Detector band-pass filters were set over 505–530 and 565–615 ranges for the green
and red emissions, respectively. To avoid signal bleed-through, images were alternatively acquired in
multitrack mode using ZEN 2012 (Carl Zeiss).
3.8. Statistical Analysis
The statistical significance of difference between controls and experimental groups for the
antimicrobial activity was evaluated using Student’s t-test. Statistical analysis was performed using
GraphPad Prism™ (Version 5.00) software (GraphPad Software, San Diego, CA, USA). A p-value < 0.05
was considered as statistically significant.
4. Conclusions
The data obtained in the present study demonstrated that the MD is effective toward Gram-positive
microorganisms such as S. aureus and E. faecalis. Moreover, it is also capable of inhibiting biofilm
formation, even when applied to suture threads. Therefore, surgical sutures coated with the MD have
the potential to reduce SSIs as well as the risk of biofilm formation post-surgery, avoiding the use of
additional antibiotic therapies with consequent weakening of the patient.
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